Lataa...
Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease
BACKGROUND: TrumenbaTM, a bivalent, factor-H binding protein meningococcal serogroup B (MenB-fHBP) vaccine was authorized for use in Canada in October 2017 for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals 10–25 years of age. The N...
Tallennettuna:
| Julkaisussa: | Can Commun Dis Rep |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Public Health Agency of Canada
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7041660/ https://ncbi.nlm.nih.gov/pubmed/32167082 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14745/ccdr.v46i23a03 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|